NaturalAntibody
NaturalAntibody is a Polish bioinformatics company that provides an AI/ML-powered platform combining proprietary antibody databases and predictive models for therapeutic antibody discovery, serving pharmaceutical, biotech, and academic research customers worldwide.
- Company typePrivate
- Founded2020
- HeadquartersSzczecin, Poland
- Headcount11–50
- GTM typeB2B
- OfferingSoftware
What NaturalAntibody does
NaturalAntibody (legal entity NATURALANTIBODY S.A.) is a privately held bioinformatics company founded in 2020 and headquartered in Szczecin, Poland, that builds an AI/ML-driven antibody discovery and optimization platform for therapeutic development. The product combines 10+ proprietary databases — including AbNGS, PairedAbNGS, AbDesign, NAStructural, Therapeutic Antibody, Patents, Antigen Specific Antibody (ASD), INDI2, and AbDesign 2.0 — with domain-specific machine learning models for paratope prediction from sequence, antibody-specific docking, developability assessment, immunogenicity scoring, language-model-based mutational suggestions, structural modeling, and sequence/structure clustering for hit picking. Standalone tools (LAP, CLAP, RIOT) are offered as free web apps alongside the main platform.
The company targets pharmaceutical companies developing antibody-based therapeutics, biotechnology companies and CROs running antibody discovery and engineering programs, and research institutes advancing drug candidates. Its go-to-market is product-led: a free cloud demo and a free downloadable on-premises version sit in front of enterprise support and customization services, with enterprise pricing not publicly disclosed. Capital structure is private (Polish S.A., KRS 0000887528), with cumulative disclosed funding of approximately $8.78M across multiple 2021–2025 rounds (including WP2 Investments as a named participant in 2023) and a PLN 9.7M EU Funds grant for the Specitope epitope-prediction project. Operating geographies, named customers, and revenue figures are not disclosed in the available data.
NaturalAntibody firmographics
Firmographics- Name
- NaturalAntibody
- Legal name
- NATURALANTIBODY S.A.
- Website
- https://naturalantibody.com
- Company type
- Private
- Founded year
- 2020
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- NaturalAntibody is a Polish bioinformatics company that provides an AI/ML-powered platform combining proprietary antibody databases and predictive models for therapeutic antibody discovery, serving pharmaceutical, biotech, and academic research customers worldwide.
- Ownership category
- akta.pro rank
NaturalAntibody industry classification
Industry- Product category
- Antibody Discovery Bioinformatics Software
- NAICS
- Software Publishers (5132), Scientific Research and Development Services (5417), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Services-Commercial Physical & Biological Research (8731), Services-Prepackaged Software (7372)
- akta.pro primary industry
- AI/ML Platforms for Drug Discovery & Experiment Optimization (HLAGAJAO)
- akta.pro secondary industries
- Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering) (HLAAAIAB), AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening) (HLAAAIAE), Engineered Protein Therapeutics (de novo/AI-designed proteins, novel scaffolds) (HLAAAAAJ), Library & Diversity Generation Platforms (display libraries, DNA-encoded libraries for biologics, variant libraries) (HLAAAIAL)
Keywords
Where NaturalAntibody is headquartered
LocationHeadquarters
- HQ city
- Szczecin
- HQ country
- Poland
- HQ region
- Europe
Offices1 record
Markets served
NaturalAntibody business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Technology or R&D, Personnel, Infrastructure, Operations, Marketing or Sales
Revenue model
- Platform SaaS Subscription: Cloud-based platform access with subscription model including free demo version and paid enterprise tiers
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Freemium | Monthly | Free Cloud Demo |
Go-to-market motion1 record
Distribution channels3 records
Marketing channels3 records
NaturalAntibody product offering
Product offeringCore offering
NaturalAntibody sells a cloud-based and on-premises antibody discovery platform that combines 10+ proprietary antibody databases with AI/ML-powered predictive models for paratope prediction, developability assessment, immunogenicity scoring, antibody-antigen docking, and mutational suggestion. The platform supports therapeutic antibody discovery workflows from sequence annotation through structural lead optimization, and is sold primarily to pharmaceutical and biotechnology enterprises via a freemium SaaS model with paid enterprise tiers and customization services.
Product overview
NaturalAntibody offers a unified platform for antibody discovery combining comprehensive databases with machine learning-powered predictive tools. The core product is the NaturalAntibody Platform, available as free cloud demo and free on-premises versions, which integrates multiple specialized databases (AbNGS, PairedAbNGS, AbDesign, NAStructural, Therapeutic Antibody, Patents, Antigen Specific Antibody, INDI2, AbDesign 2.0) alongside analytical tools for sequence engineering, structural modeling, antibody docking, developability prediction, and hit picking. Supporting standalone tools include LAP (Liability Antibody Profiler) for liability prediction, CLAP for clustering-based hit picking, and RIOT for immunoglobulin sequence overview.
Differentiator
Problem solved
Functional benefit
Products and services
- NaturalAntibody Platform Cloud-based and on-premises antibody discovery platform integrating data management, predictive analytics, structural modeling, and sequence engineering tools for therapeutic antibody optimization, sold to pharmaceutical and biotechnology enterprise customers.
- AbNGS Database Large database of immunoglobulin sequences for immunological and machine learning applications, accessible separately from the main platform.
- PairedAbNGS Database Database containing paired antibody next-generation sequencing data for paired heavy and light chain analysis, available separately from the platform.
- AbDesign Database Database for antibody design data supporting computational antibody engineering workflows, available separately from the main platform.
- NAStructural Database Database containing structural data for nucleic acid-antibody complexes, available separately from the main platform.
- Therapeutic Antibody Database Comprehensive database of therapeutic antibody data including clinical trial information and approved therapeutics, available separately from the main platform.
- Patents Database Database of antibody-related patents for intellectual property research and analysis, available separately from the main platform.
- Antigen Specific Antibody Database (ASD) Database containing antigen-specific antibody sequences and related immunological data, available separately from the main platform.
- INDI2 Database Database supporting immune repertoire analysis and antibody discovery research, available separately from the main platform.
- AbDesign 2.0 Database Updated version of the antibody design database with enhanced features for computational antibody engineering, available separately from the main platform.
- LAP - Liability Antibody Profiler Standalone tool for predicting developability issues and liabilities in antibody sequences using biophysical descriptors, available as a separate web app.
- CLAP - Clustering App Standalone application for hit picking using multiple clustering methods including sequence, structure, paratope, and embedding clustering, available as a separate web app.
- RIOT - Rapid Immunoglobulin Overview Tool Standalone tool for rapid analysis and visualization of immunoglobulin sequences and repertoire data, available as a separate web app.
- Enterprise Support & Customization Platform support and customization services for enterprise customers with specific computational or deployment requirements, sold alongside platform subscriptions.
Companies that use NaturalAntibody
Customer profileSegments3 records
Ideal customer profiles3 records
NaturalAntibody technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature13 records
NaturalAntibody partnerships and signals
Strategic signalScale indicators3 records
Recent moves6 records
Expansion highlights5 records
NaturalAntibody competitors and assessment
Company assessmentDirect peers
- Schrödinger: Computational chemistry and biology platform whose LiveDesign and Biologics modules address antibody and protein therapeutic design, including developability and structural modeling. Closely comparable software-led approach to computational antibody and biologics R&D for pharma/biotech buyers.
- Absci: Generative AI platform for de novo antibody and protein design, combining in silico design with wet-lab validation. Directly comparable in applying AI/ML to antibody sequence engineering and lead optimization, serving the same pharma/biotech customer base.
- BioMap: Builds AI foundation models for proteins, including antibody-specific models, and offers a platform for protein/antibody sequence design and analysis. Directly comparable as an AI/ML antibody informatics platform with similar target users in pharma and biotech.
- BenchSci: AI-driven reagent selection and antibody research platform for pharma/biotech scientists, helping them choose the right antibodies and interpret experimental data. Comparable SaaS business model, target customer (biopharma R&D scientists), and AI/ML applied to antibody-related decision-making.
- AbCellera Biologics: AI-driven antibody discovery platform combining immune repertoire sequencing, ML, and internal wet-lab capabilities to deliver therapeutic antibody candidates. Directly comparable target customer base (pharma/biotech) and overlapping use cases around antibody sequence analysis, developability, and lead selection.
- BigHat Biosciences: AI/ML-driven antibody design platform that integrates machine learning with high-throughput wet-lab characterization to engineer therapeutic antibodies. Comparable focus on ML-guided antibody sequence optimization, developability, and serving pharma/biotech partners.
Emerging players
- Cradle Bio: Generative AI platform for protein engineering with a particular focus on binding affinity and stability optimization. Comparable in applying ML to protein/antibody sequence design, but with a narrower focus on engineering and less emphasis on integrated antibody databases.
- Adaptyv Bio: AI-driven protein engineering platform combining ML sequence design with high-throughput wet-lab validation for therapeutic protein and antibody optimization. Comparable emerging player with overlapping ML-guided protein engineering use cases, though smaller and wet-lab integrated.
Broad incumbents
- Atreca: Antibody discovery company combining immune repertoire analysis with computational methods to identify therapeutic antibody candidates. Comparable focus on antibody sequence informatics and pharma/biotech partnerships, though with a more discovery-services model rather than software.
- Insilico Medicine: End-to-end AI-driven drug discovery company spanning target identification, generative chemistry, and clinical development, with growing biologics capabilities. Broader incumbent in AI drug discovery with overlapping AI/ML platform technology serving similar pharma customers.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights6 records
Customer concentration
NaturalAntibody social profiles
Digital presenceNaturalAntibody financial estimates
Financial estimateRevenue estimate
Valuation estimate
NaturalAntibody leadership team
Management profileNumber of profiles
Profiles2 records
NaturalAntibody funding detail
Funding detailFunding overview
Funding rounds8 records
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
NaturalAntibody M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about NaturalAntibody
What does NaturalAntibody do?
NaturalAntibody sells a cloud-based and on-premises antibody discovery platform that combines 10+ proprietary antibody databases with AI/ML-powered predictive models for paratope prediction, developability assessment, immunogenicity scoring, antibody-antigen docking, and mutational suggestion. The platform supports therapeutic antibody discovery workflows from sequence annotation through structural lead optimization, and is sold primarily to pharmaceutical and biotechnology enterprises via a freemium SaaS model with paid enterprise tiers and customization services.
Is NaturalAntibody a public or private company?
NaturalAntibody is a private company. It is classified as venture growth investor backed and is currently operating.
When was NaturalAntibody founded?
NaturalAntibody was founded in 2020. It employs 11 to 50 people.
Where is NaturalAntibody based?
NaturalAntibody is headquartered in Szczecin, Poland, in the Europe region.
How does NaturalAntibody make money?
One revenue line is on record: platform SaaS Subscription.
Who are NaturalAntibody's main competitors?
Direct peers on record are Schrödinger, Absci, BioMap, BenchSci, AbCellera Biologics and BigHat Biosciences. Emerging players are Cradle Bio and Adaptyv Bio. Broad incumbents are Atreca and Insilico Medicine.
Does NaturalAntibody have an API?
No public API is recorded for NaturalAntibody.
What industry is NaturalAntibody in?
NaturalAntibody's product category is Antibody Discovery Bioinformatics Software. Its primary akta.pro industry code is HLAGAJAO, AI/ML Platforms for Drug Discovery & Experiment Optimization, with a secondary code of HLAAAIAB, Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering). Its NAICS code is 5132 and its SIC code is 8731.